Exploiting our knowledge of NF-kappaB signaling for the treatment of mammary cancer.
Nuclear Factor-kappaB (NF-kappaB) has been implicated in the lobuloalveolar development of the mammary gland. In breast cancer its activation has been linked to tumor progression via stimulation of cell proliferation, pro-survival, and angiogenesis pathways and metastasis. Whether NF-kappaB activation in the immune system influences mammary cancer remains unclear. In addition to the constitutive activation frequently found in mammary carcinoma tissue, radio- and chemotherapeutic agents used in the treatment of mammary cancer can lead to activation of NF-kappaB. This effect has been postulated to contribute to the development of resistance to these agents and suggests the use of NF-kappaB inhibitors as sensitizers for therapy. The review describes principle targets and drugs used to inhibit NF-kappaB function and discusses future perspectives in the use of these inhibitors for the treatment of mammary cancer.
Haffner
Michael C
MC
Division Medical Biochemistry, Biocenter, Innsbruck Medical University, Fritz-Pregl-Str. 3, A-6020 Innsbruck, Austria.
Berlato
Chiara
C
Doppler
Wolfgang
W
D000818:Animals; D000970:Antineoplastic Agents; D017209:Apoptosis; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000503:physiopathology*; D019008:Drug Resistance, Neoplasm; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D016328:NF-kappa B / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D009362:Neoplasm Metastasis / Q000503:physiopathology; D012377:Rodentia
D000970:Antineoplastic Agents; D016328:NF-kappa B